Market Research Logo

Cerus Corp (CERS) - Product Pipeline Analysis, 2018 Update

Summary

Cerus Corp (Cerus) is a biomedical products company that focuses in the field of blood transfusion safety. It develops and commercializes the INTERCEPT Blood System to enhance blood safety. INTERCEPT Blood System reduces the risk of transfusion-transmitted infections by inactivating a wide range of pathogens including viruses, bacteria and parasites present in donated blood. The product is for use with three blood components, platelets, plasma and red blood cells. Cerus is marketed and sold in several countries worldwide including the US, Belgium, Kuwait, France, Spain, Portugal, Switzerland, CIS countries and other countries. Cerus is headquartered in Concord, California, the US.

This report is a source for data, analysis, and actionable intelligence on the company’s portfolio of pipeline products. The report provides key information about the company, its major products and brands.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage.

Scope:

  • The report reviews detailed company profile with information on business description, key company facts, major products and services, key competitors, key employees, locations and subsidiaries and recent developments
  • The report analyzes all pipeline products in development for the company Cerus Corp
  • The report provides pipeline analysis on all pipeline products of the company (by equipment type, by indication, by development stage, and by trial status)
  • The report covers detailed information on each pipeline product with information on pipeline territory, stage of development, device class, regulatory path, indication(s), application(s) and estimated launch date
  • The report provides detailed description of products in development, technical specification and functions
  • The report also covers ongoing clinical trials (wherever applicable) with information on trial name, trial objective, sponsor, trial design , trial status and phase, estimated start and end date.
Reasons to Buy:
  • Develop business strategies by understanding the trends and developments driving the medical devices pipeline and technology landscape
  • Design and develop your product development, marketing and sales strategies by understanding the competitor portfolio
  • To formulate effective Research & Development strategies
  • Develop market-entry and market expansion strategies
  • Exploit in-licensing and out-licensing opportunities by identifying products, most likely to ensure a robust return
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop competition strategies by identifying the status and likely launch of the competitors’ pipeline products through review of the clinical trials, stage and of development, etc
  • Identify, understand and capitalize the next high-value products that your competitor would add in its portfolio
Note: Some sections may be missing if data is unavailable for the company


Cerus Corp Company Overview
Cerus Corp Company Snapshot
Cerus Corp Pipeline Products and Ongoing Clinical Trials Overview
Cerus Corp – Pipeline Analysis Overview
Business Description
Cerus Corp - Key Facts
Cerus Corp - Major Products and Services
Cerus Corp Pipeline Products by Development Stage
Cerus Corp Ongoing Clinical Trials by Trial Status
Cerus Corp Pipeline Products Overview
INTERCEPT Blood System - Platelets
INTERCEPT Blood System - Platelets Product Overview
INTERCEPT Blood System - Platelets Clinical Trial
INTERCEPT Blood System - Red Blood Cells
INTERCEPT Blood System - Red Blood Cells Product Overview
INTERCEPT Blood System - Red Blood Cells Clinical Trial
INTERCEPT Blood System - Zika Virus
INTERCEPT Blood System - Zika Virus Product Overview
Cerus Corp - Key Competitors
Cerus Corp - Key Employees
Cerus Corp - Key Employee Biographies
Cerus Corp - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Recent Developments
Cerus Corp, Recent Developments
May 16, 2018: Cerus Announces Additional BARDA Funding to Support Development of INTERCEPT Blood System for Red Blood Cells
May 08, 2018: Cerus Reports First Quarter 2018 Results
Apr 02, 2018: Cerus’ RedeS Phase 3 Red Blood Cell Study Expands Into the Continental U.S.
Mar 13, 2018: Cerus Announces the Fourth Biologics License Application (BLA) Approval for a U.S. Blood Center Customer
Mar 08, 2018: Cerus Reports Fourth Quarter And Year End 2017 Financial Results
Jan 23, 2018: Cerus Reports Positive Top-Line Results from Chronic Anemia Phase 3 Study Evaluating INTERCEPT Red Blood Cells in Thalassemia Patients
Jan 08, 2018: Cerus Announces Preliminary Product Revenue Results for Fourth Quarter and Full Year 2017
Nov 07, 2017: Cerus Receives IDE Approval to Initiate Phase III ReCePI Study
Nov 02, 2017: Cerus Corporation Reports Third Quarter 2017 Results
Oct 31, 2017: Cerus and Kedrion Biopharma Enter Distribution Agreement for the Full INTERCEPT Blood System Portfolio in Italy
Appendix
Methodology
About GlobalData
Contact Us
Disclaimer
List of Tables
Cerus Corp Pipeline Products and Ongoing Clinical Trials Overview
Cerus Corp Pipeline Products by Equipment Type
Cerus Corp Pipeline Products by Indication
Cerus Corp Ongoing Clinical Trials by Trial Status
Cerus Corp, Key Facts
Cerus Corp, Major Products and Services
Cerus Corp Number of Pipeline Products by Development Stage
Cerus Corp Pipeline Products Summary by Development Stage
Cerus Corp Ongoing Clinical Trials by Trial Status
Cerus Corp Ongoing Clinical Trials Summary
INTERCEPT Blood System - Platelets - Product Status
INTERCEPT Blood System - Platelets - Product Description
INTERCEPT Blood System - Platelets - A Randomized, Double-Blind, Phase I, Dose-escalation Study for the Safety of Whole Blood Treated with Amustaline (S-303) and Glutathione (GSH), a Pathogen Inactivation System, and Transfused to Anemic Adult Cancer Patients
INTERCEPT Blood System - Red Blood Cells - Product Status
INTERCEPT Blood System - Red Blood Cells - Product Description
INTERCEPT Blood System - Red Blood Cells - A Randomized Controlled Study to Evaluate Efficacy and Safety of S 303 Treated Red Blood Cells (RBC) in Subjects with Thalassemia Major Requiring Chronic RBC Transfusion
INTERCEPT Blood System - Red Blood Cells - A Randomized, Double-blind, Controlled, Parallel Group Study with the INTERCEPT Blood System for Red Blood Cells in Regions at Potential Risk for Zika Virus Transfusion-transmitted Infections (RedeS Study) and Treatment Use Open-label Extension Study
INTERCEPT Blood System - Red Blood Cells - A Randomized, Double-Blind, Phase I, Dose-escalation Study for the Safety of Whole Blood Treated with Amustaline (S-303) and Glutathione (GSH), a Pathogen Inactivation System, and Transfused to Anemic Adult Cancer Patients
INTERCEPT Blood System - Red Blood Cells - A Randomized, Double-blinded, Controlled, Parallel Group, Non-inferiority, Phase III Study to Evaluate the Efficacy and Safety of the INTERCEPT Blood System for Red Blood Cells in Patients undergoing Complex Cardiac Surgery Procedures
INTERCEPT Blood System - Red Blood Cells - Measurement of the Recovery and Lifespan of Red Blood Cells from Pathogen-reduced, Stored Blood Units Using Cellular Biotinylation
INTERCEPT Blood System - Zika Virus - Product Status
INTERCEPT Blood System - Zika Virus - Product Description
Cerus Corp, Key Employees
Cerus Corp, Key Employee Biographies
Cerus Corp, Subsidiaries
Glossary
List of Figures
Cerus Corp Pipeline Products by Equipment Type
Cerus Corp Pipeline Products by Development Stage
Cerus Corp Ongoing Clinical Trials by Trial Status

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report